Quick Answer
Bioventus Inc. reported Stockholders Equity of $184.11 million for the year ending 2025.
- Bioventus Inc. showed an increase of +24.4% in Stockholders Equity from 2024 to 2025.
- This data is from Bioventus Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $142.39 million | Q2 2021: $141.56 million | Q3 2021: $152.50 million | Q1 2022: $449.78 million | Q2 2022: $447.98 million | Q3 2022: $343.40 million | Q1 2023: $188.51 million | Q2 2023: $183.20 million | Q3 2023: $177.53 million | Q1 2024: $171.28 million | Q2 2024: $150.94 million | Q3 2024: $148.74 million | Q1 2025: $148.14 million | Q2 2025: $161.24 million | Q3 2025: $166.10 million.
- Over the full 5 years of available data (2021 to 2025), Bioventus Inc.'s Stockholders Equity has declined by 59.9%.
- Historical annual values: Fiscal year 2025: $184.11 million | Fiscal year 2024: $147.94 million | Fiscal year 2023: $173.59 million | Fiscal year 2022: $325.24 million | Fiscal year 2021: $458.92 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: